D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Vericel Corporation (NASDAQ:VCEL), a leader in cell therapies for the treatment of patients with serious diseases and conditions, has reached a new 52-week high, with its stock price soaring to $61.5. The company, now valued at $3.03 billion, maintains strong financial health with a current ratio of 4.61, indicating robust liquidity. This milestone reflects a significant period of growth for the company, which has seen its stock value climb by an impressive 36.6% over the past year. Investors have shown increasing confidence in Vericel’s market position and its portfolio of specialized cell therapy products, which are gaining traction in the medical community. The company’s robust performance, including revenue growth of 22.48% in the last twelve months, and promising outlook have contributed to the stock’s upward trajectory, marking a notable achievement in its financial history. According to InvestingPro, which offers comprehensive analysis and 13 additional key insights, the company’s current valuation appears to be above its Fair Value.
In other recent news, Vericel Corporation’s preliminary Q4 revenue fell short of expectations, with total revenue landing between $75.2 million and $75.7 million, below the estimated $77.9 million. However, the company’s MACI product generated between $68.2 million and $68.7 million in revenue, surpassing analyst estimates. The company’s preliminary Epicel and NexoBrid revenues were lower than estimated. Looking ahead, Vericel projects total revenue growth of 20-23% for fiscal year 2025. The company has received positive attention from Truist Securities and TD Cowen, both upgrading their price targets for the company’s shares. On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a $60.00 price target for Vericel. Additionally, Canaccord Genuity restated their Buy rating on shares of Vericel, maintaining a price target of $64.00. These are recent developments in Vericel Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.